Glenmark Life Sciences Statistics

Total Valuation

Glenmark Life Sciences has a market cap or net worth of INR 128.13 billion. The enterprise value is 123.82 billion.

Market Cap	128.13B
Enterprise Value	123.82B

Important Dates

The last earnings date was Friday, October 25, 2024.

Earnings Date	Oct 25, 2024
Ex-Dividend Date	n/a

Share Statistics

Glenmark Life Sciences has 122.53 million shares outstanding. The number of shares has increased by 0.28% in one year.

Current Share Class	n/a
Shares Outstanding	122.53M
Shares Change (YoY)	+0.28%
Shares Change (QoQ)	+0.17%
Owned by Insiders (%)	0.00%
Owned by Institutions (%)	4.70%
Float	30.64M

Valuation Ratios

The trailing PE ratio is 30.34 and the forward PE ratio is 23.61. Glenmark Life Sciences's PEG ratio is 1.52.

PE Ratio	30.34
Forward PE	23.61
PS Ratio	5.81
PB Ratio	5.05
P/TBV Ratio	n/a
P/FCF Ratio	48.35
P/OCF Ratio	n/a
PEG Ratio	1.52

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 20.45, with an EV/FCF ratio of 46.73.

EV / Earnings	29.24
EV / Sales	5.62
EV / EBITDA	20.45
EV / EBIT	22.43
EV / FCF	46.73

Financial Position

The company has a current ratio of 4.52, with a Debt / Equity ratio of 0.01.

Current Ratio	4.52
Quick Ratio	2.81
Debt / Equity	0.01
Debt / EBITDA	0.03
Debt / FCF	0.06
Interest Coverage	381.48

Financial Efficiency

Return on equity (ROE) is 17.18% and return on invested capital (ROIC) is 13.90%.

Return on Equity (ROE)	17.18%
Return on Assets (ROA)	11.43%
Return on Capital (ROIC)	13.90%
Revenue Per Employee	10.95M
Profits Per Employee	2.10M
Employee Count	2,014
Asset Turnover	0.73
Inventory Turnover	1.52

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +67.18% in the last 52 weeks. The beta is 0.16, so Glenmark Life Sciences's price volatility has been lower than the market average.

Beta (5Y)	0.16
52-Week Price Change	+67.18%
50-Day Moving Average	1,120.87
200-Day Moving Average	931.80
Relative Strength Index (RSI)	43.66
Average Volume (20 Days)	125,456

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Glenmark Life Sciences had revenue of INR 22.05 billion and earned 4.24 billion in profits. Earnings per share was 34.46.

Revenue	22.05B
Gross Profit	11.73B
Operating Income	5.52B
Pretax Income	5.68B
Net Income	4.24B
EBITDA	6.03B
EBIT	5.52B
Earnings Per Share (EPS)	34.46

Full Income Statement

Balance Sheet

The company has 4.46 billion in cash and 159.77 million in debt, giving a net cash position of 4.30 billion or 35.12 per share.

Cash & Cash Equivalents	4.46B
Total Debt	159.77M
Net Cash	4.30B
Net Cash Per Share	35.12
Equity (Book Value)	25.38B
Book Value Per Share	207.20
Working Capital	16.32B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 4.17 billion and capital expenditures -1.52 billion, giving a free cash flow of 2.65 billion.

Operating Cash Flow	4.17B
Capital Expenditures	-1.52B
Free Cash Flow	2.65B
FCF Per Share	21.63

Full Cash Flow Statement

Margins

Gross margin is 53.21%, with operating and profit margins of 25.03% and 19.21%.

Gross Margin	53.21%
Operating Margin	25.03%
Pretax Margin	25.76%
Profit Margin	19.21%
EBITDA Margin	27.34%
EBIT Margin	25.03%
FCF Margin	12.02%

Dividends & Yields

This stock pays an annual dividend of 22.50, which amounts to a dividend yield of 2.15%.

Dividend Per Share	22.50
Dividend Yield	2.15%
Dividend Growth (YoY)	314.29%
Years of Dividend Growth	1
Payout Ratio	65.10%
Buyback Yield	-0.28%
Shareholder Yield	1.87%
Earnings Yield	3.30%
FCF Yield	2.07%

Dividend Details

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	n/a